CRT 2026

Final Thoughts & Panel Discussion

Moderator(s)

• 

  Timothy D. Henry, MD

  Director, The Carl and Edyth Lindner Center for Research and Education
  The Christ Hospital
  Bellevue, Kentucky, United States

  Disclosure(s): No financial relationships to disclose

Panel Discussant(s)

• 

  Jeff W. Chambers, MD, FSCAI, FACC

  Director of the percutaneous Coronary Interventions
  Metropolitian Heart and Vascular Institute
  Minneapolis, Minnesota, United States

  Disclosure(s): Zoll/Therox: Consulting Fees (e.g., advisory boards) (Ongoing)
• 

  Michael J. Lim, MD

  Interventional Cardiologist
  Poplar Bluff Regional Medical Center
  Poplar Bluff, Missouri, United States

  Disclosure(s): Abiomed / Johnson & Johnson: Consulting Fees (e.g., advisory boards) (Ongoing); Zoll/Therox: Consulting Fees (e.g., advisory boards) (Ongoing)
• 

  Ramon Quesada, MD, FACP, FACC, FSCAI

  Medical Director of Interventional Cardiology, Structural Heart & Cardiac Research
  Miami Cardiac & Vascular Institute
  Miami, Florida, United States

  Disclosure(s): No financial relationships to disclose
• 

  Gregg W. Stone, MD, FACC, MSCAI

  Physician
  Mount Sinai
  New York, New York, United States

  Disclosure(s): Cardiac Success, Ancora, Cagent, Applied Therapeutics, Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Valfix, Xenter, Vascentis: Stock-privately held company (Ongoing); Cardiac Success, Occlutech, Ablative Solutions, Oxitope, Elixir, Impulse Dynamics, Asceneuron, Myochron, Vesalio: Consulting Fees (e.g., advisory boards) (Terminated); Colibri, Remote Cardiac Enablement, Valfix, Zoll, HeartFlow, Shockwave, Ancora, Adona Medical, Abbott, HighLife, Elucid Bio, Aria, Alleviant, FBR Medical, Bioventrix, MedHub, Biotyx Medical: Consulting Fees (e.g., advisory boards) (Ongoing); Shockwave, Biosense-Webster, Bioventrix, Abbott, Abiomed, Cardiovascular Systems Inc, Phillips, Pulnovo, V-wave and PCORI via Weill Cornell Medical Center.: Grant/Research Support (Ongoing)